about
Lipoprotein(a) as a cardiovascular risk factor: current statusEffects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefitPCSK9 inhibition in the management of hyperlipidemia: focus on evolocumabRecommendation to Reduce Patients' Blood Pressure and Cholesterol Medication CostsReducing Medication Costs to Prevent Cardiovascular Disease: A Community Guide Systematic ReviewGlycaemic, blood pressure and cholesterol control in 25 629 diabeticsNiacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place?A review of the effect of omega-3 polyunsaturated fatty acids on blood triacylglycerol levels in normolipidemic and borderline hyperlipidemic individualsProfile of evolocumab and its potential in the treatment of hyperlipidemiaRole of colesevelam in combination lipid-lowering therapyDevelopment of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disordersUnmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studiesIs hyperlipidemia a potential protective factor against intraoperative awareness in cardiac surgery?Diabetic retinopathy and systemic factorsLipid-modifying therapy in the elderlyLipoprotein(a) in nephrological patientsChronic Fructose Ingestion as a Major Health Concern: Is a Sedentary Lifestyle Making It Worse? A Review.A review on the traditional Chinese medicinal herbs and formulae with hypolipidemic effect.Considering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefitsThe impact of sleeve gastrectomy on hyperlipidemia: a systematic review.Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretinsFunctional alterations of myeloid cell subsets in hyperlipidaemia: relevance for atherosclerosis.Pharmacogenetics of lipid diseases.Diacylglycerol oil for the metabolic syndrome.Mechanisms of dyslipoproteinemias in systemic lupus erythematosusAn update on accumulating exercise and postprandial lipaemia: translating theory into practiceAcute pancreatitis secondary to hyperlipidemia in an 11-year-old girl: a case report and review of literature.Management of hyperlipidemia with statins in the older patient.Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapyPostprandial Hyperlipidemia and Remnant Lipoproteins.Hyperlipidemia: a new therapeutic target for diabetic neuropathy.Beneficial effect of LDL-apheresis in refractory nephrotic syndrome.Lipids in hepatic glycogen storage diseases: pathophysiology, monitoring of dietary management and future directions.Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6) Is a Novel Nutritional Therapeutic Target for Hyperlipidemia, Non-Alcoholic Fatty Liver Disease, and Atherosclerosis.Hyperlipoproteinaemia(a) - apheresis and emerging therapies.Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a).Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up.Potential Role of Thyroid Receptor β Agonists in the Treatment of Hyperlipidemia.Hypolipidemic, anti-obesity, anti-inflammatory, anti-osteoporotic, and anti-neoplastic properties of amine carboxyboranes.Postprandial lipemia: factoring in lipemic response for ranking foods for their healthiness.
P921
Q10354103-413FB226-475B-4260-8B4F-8D0AFA5FDDE9Q12200764-8733FC91-7AF3-4D07-A824-B76FF46C24F2Q1240093-EF884D10-A30A-4748-A6B4-0CD782DE01B0Q134658-48278148-0E1B-4EB2-B72E-926BBC18FDCBQ256502-D2EE6D10-C7CC-4092-93A3-E6E759986578Q2701912-EE6850F8-15B4-435A-9FB3-048DB4D61BD7Q321285-3D5D7C11-9277-4620-BE98-FA32928EFAF4Q3294635-3C02961D-2230-4588-9931-47799D6891F4Q3496452-1078E09A-F3C5-40C7-B426-E60309A97F30Q384295-981E63BD-D703-4283-AB54-C6BE95089858Q417740-7F4F662C-4D13-4C1F-964D-5EC680E0D3DCQ417942-AEF62859-8BBC-45C1-BE14-E9AFCD283920Q418006-26E8BD01-A951-4DFE-9377-59F626C59C96Q419724-FE13F27F-52C0-43DE-B482-706D975BE909Q423439-9AC6E1F4-A58C-4F20-B789-E140EAE9F27EQ5268499-8B0C2842-5E00-41A7-A3B1-CF6ABAACFD57Q577387-B021CAAA-2768-4559-8ADF-80F00D070618Q668093-DBA8547E-C9E8-4BFF-8217-57F0AB2D3B65Q670131-F7CBB6C3-9381-42AB-A273-5549C1C319B8Q899036-E8767E84-20A7-4E12-BA0D-D515942A4DDF
P2175
Q24623225-7FB1D70D-BF51-4BDA-89C3-57CE54FDDF62Q24650533-E5DEFF4D-98E9-4B7E-9044-D78EDABFBDCDQ26747776-59D1CEEC-FE21-4AEB-8C55-57EB6BE064CAQ26775538-6ADBCFD1-47B7-463C-A1C0-B587E74E0D84Q26775544-120B44CE-6126-461D-B9B9-29EA63D2D3D6Q26781082-CD62BFD2-519B-41B2-AFCB-5BAFE0CFB7E7Q26799534-73E61840-E89F-4E04-8087-A2A4FDED7BB0Q26863499-EDE87913-1A73-422C-B075-A412663CE47BQ27004235-C4E7FA68-E4F3-4C1E-A8B9-4C1AB5C6DA0FQ27016027-82031F65-B3FC-455E-8246-C40B97A63709Q28070296-82541CC9-BCC4-4744-A78B-E38390696843Q28072161-69C2CE1C-0779-4052-AA8E-B48FC7D282CFQ28076507-77B8D9E7-B2B1-4185-B555-4ACD63A3786BQ28082046-FFC040CE-0DFE-42A9-9DDD-49F32B8171E8Q28088296-7FE7E9E0-D8D7-4ABD-9314-FC2FDB25883CQ30236043-4D1D0771-4143-4AA0-BC62-A95EC8BC912BQ33851818-666F9327-E9EC-4EDB-B594-7D547C4A64CDQ33942724-3CCFE878-5AE5-4646-9108-BCEDDDA14608Q34566253-CF7D9CA0-DFA5-4F91-B0F1-DB5DCA7A5E2AQ35055951-AA05ADAB-8F54-453A-9DB5-B6FFF97A02DDQ35249760-CF1B9E98-B82A-43CC-89B9-5A3B0BF6D570Q35889058-1B19AC84-9C49-4F8B-ADA8-68271BFC3A25Q35985478-6DC14276-0606-4423-B65A-2B6FCA9E0920Q36449488-9C055F6B-2B04-4D34-ACA5-32D720B5AF17Q36502252-048FBBC9-7264-40D5-80C8-78115429F2B4Q36595220-BD854856-987C-49E7-A012-C5D37BD7697CQ36760788-399FA301-70AB-4827-8AB9-BE34EF9A30CAQ37018964-0E7A967E-CE63-4433-B3C2-206FEB39810CQ37115301-BB79E83B-243B-4B95-8038-62F7AE63AFD4Q37639159-975A8032-48B7-493A-8E7C-D60258CC74E4Q37659233-FCBB65B8-5FB4-4D42-8A90-AF1BEBDEA056Q37714609-BC7EE45A-1EC1-4A72-A7A1-2BA382E4095AQ38336909-0AD1E4BE-8397-4023-A636-665E80382C9EQ38517043-C81944B0-6324-42F3-BE0F-ED71D2406D55Q38968510-62E23FD7-3B1A-4422-A1F0-92B74C93C257Q39148923-E932BACC-BC64-4C06-99D5-2CB89BCDF9A4Q39458225-F645A46D-10EB-4471-8BDA-9D8977F6AB2CQ40069909-AC5A0544-EF52-4E3B-8635-5350B437B7B9Q40612573-851D37B0-201A-4FD6-9472-02F1FAF416F4Q41716162-7A23A732-2335-483B-BD3A-9E6C5BB93C9C
P921
description
Human disease
@en
Krankheit
@de
مرض يصيب الإنسان
@ar
name
familial hyperlipidemia
@en
familiær hyperlipidemi
@nn
hiperlipidemia familiar
@es
hiperlipidèmia familiar
@ca
hyperlipidémie primitive
@fr
فرط شحميات الدم العائلي
@ar
type
label
familial hyperlipidemia
@en
familiær hyperlipidemi
@nn
hiperlipidemia familiar
@es
hiperlipidèmia familiar
@ca
hyperlipidémie primitive
@fr
فرط شحميات الدم العائلي
@ar
altLabel
familial hyperlipoproteinemia
@en
hyperlipemia
@en
hyperlipidaemia
@en
hyperlipidémie essentielle
@fr
primary hyperlipemia
@en
فرط ليبيدات الدم العائلي
@ar
prefLabel
familial hyperlipidemia
@en
familiær hyperlipidemi
@nn
hiperlipidemia familiar
@es
hiperlipidèmia familiar
@ca
hyperlipidémie primitive
@fr
فرط شحميات الدم العائلي
@ar
P2176
P2888
P1995
P2176
P2892
P31
P3841
HP:0010980